---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-24-024574"
form_type: "8-K"
ticker: "RCKT"
cik: "0001281895"
company_name: "ROCKET PHARMACEUTICALS, INC."
filed_at: "2024-05-06T23:59:59+00:00"
generated_at: "2026-06-02T21:48:12.077351+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Rocket Pharma Q1 net loss $62.1M; cash $330.3M; EMA accepted MAA for FA, PDUFA date June 30 for LAD-I

## Summary
- Net loss of $62.1M ($0.66/sh) vs $58.3M ($0.73/sh) in Q1 2023; G&A rose to $22.1M on commercial prep.
- Cash and investments $330.3M as of March 31, 2024; expected operational runway into 2026.
- EMA accepted MAA for RP-L102 (Fanconi Anemia); BLA submission to FDA expected H1 2024.
- PDUFA date for KRESLADI (severe LAD-I) set for June 30, 2024; commercial preparations underway.
- Appointed Aaron Ondrey as CFO and Meg Dodge as VP of Investor Relations & Corporate Communications.

## SEC filing metadata
- accession: 0001140361-24-024574
- form_type: 8-K
- ticker: RCKT
- cik: 0001281895
- company_name: ROCKET PHARMACEUTICALS, INC.
- filed_at: 2024-05-06T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1281895/000114036124024574/0001140361-24-024574-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1281895/000114036124024574/ef20028575_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-24-024574
- JSON: https://secwatch.observer/filing/0001140361-24-024574.json
- Plain text: https://secwatch.observer/filing/0001140361-24-024574.txt

## Key facts
- Earnings Releases
  ROCKET PHARMACEUTICALS, INC. reported preliminary financial results for the quarter ended March 31, 2024.
  - Period: the quarter ended March 31, 2024
  - Result: preliminary results
  source text: On May 6, 2024, Rocket Pharmaceuticals, Inc. (the “Company”) announced certain preliminary financial information for the quarter ended March 31, 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1281895/000114036124024574/0001140361-24-024574-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.